Wells Fargo’s Travere Therapeutics TVTX Stock Holding History

Wells Fargo’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-168,000	Closed	-$4.02M	–	7358
2025 Q3	$4.02M	Hold	168,000	–	–	﹤0.01%	2748
2025 Q2	$2.49M	Hold	168,000	–	–	﹤0.01%	3051
2025 Q1	$3.01M	Hold	168,000	–	–	﹤0.01%	2828
2024 Q4	$2.93M	Hold	168,000	–	–	﹤0.01%	2893
2024 Q3	$2.35M	Buy	+168,000	New	+$1.75M	﹤0.01%	2933

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wells Fargo's TVTX Position: Q1 2026 in Review

Wells Fargo reduced its Travere Therapeutics (TVTX) stake by 44% in Q1 2026, selling an estimated $2.08M and leaving 89,406 shares worth $2.66M. The position accounts for ﹤0.01% of the portfolio, ranked #3055.

Wells Fargo first reported a position in TVTX in Q2 2014 and has held it in 48 quarters since. The position peaked at $10.6M in Q2 2015. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

Wells Fargo held 89,406 shares of Travere Therapeutics worth $2.66M as of Q1 2026.
Wells Fargo sold 69,428 Travere Therapeutics shares in Q1 2026, an estimated $2.08M.
Travere Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #3055 holding.
Wells Fargo first reported a position in Travere Therapeutics in Q2 2014 and has held it in 48 quarters since.
Wells Fargo's Travere Therapeutics position peaked at $10.6M in Q2 2015.
260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.